NEW YORK (GenomeWeb) – Meridian Bioscience today initiated revenue and earnings guidance for its fiscal 2016 and said that revenues and earnings for fiscal 2015 are expected to be at the low end of its previously stated guidance range. 

The firm said that for fiscal 2016, which starts on Oct. 1, it expects net revenues to grow between 3 percent and 5 percent on a constant currency basis, translating to a revenue range of $195 million to $200 million. EPS is expected to be in the range of $.86 to $.90. 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.